Skip to main content
Abdominal Aortic AneurysmDrugPhase 2

What this study is

In this research, the investigators are looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s. AAA is an abnormal enlargement of the aorta, which is the large artery in the abdomen (stomach area). The enlargement of the aorta carries a risk that it will rupture and cause life-threatening bleeding in the abdomen (belly). In this study the investigators hope to learn how metformin is associated with the enlargement or change in size of the AAA in study participants. Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?

What's being tested

  • Metformin

    Intervention · DRUG

    Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?

  • Placebo

    Intervention · OTHER

    One group will be randomized to receive the study drug Metformin and the other group will receive a placebo

Study details

Official title
LIMItIng AAA With meTformin (LIMIT) Trial
Sponsor
Stanford University
Conditions
Abdominal Aortic Aneurysm
Enrolling
314 people
Starts
2022-02-28
Est. completion
2028-06-30
Design
Triple-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗